What is Zilia?
Zilia is pioneering a novel approach in medical diagnostics by developing a platform designed to non-invasively measure biomarkers within the eye. The company's initial focus is on ocular oximetry, utilizing a sophisticated integration of photonics and artificial intelligence. This technology aims to harness the unique optical properties of the eye and its direct physiological links to the vascular system and brain, thereby capturing crucial health data related to both ocular conditions and overall systemic well-being.
How much funding has Zilia raised?
Zilia has raised a total of $4M across 1 funding round:
Angel/Seed
$4M
Angel/Seed (2021): $4M with participation from Anges Québec
Key Investors in Zilia
Anges Québec
Anges Québec is an angel investor network that typically invests in early-stage Quebec-based technology companies, providing both capital and strategic guidance.
What's next for Zilia?
The substantial enterprise-level investment positions Zilia for significant scaling and further research and development. This capital infusion is expected to accelerate the refinement of its AI-driven diagnostic tools and potentially expand its application beyond ocular oximetry to a broader spectrum of health monitoring. The company's strategic focus on leveraging the eye as a window to systemic health suggests a future trajectory aimed at becoming a leader in non-invasive diagnostic technologies.
See full Zilia company page
